Nanocrine is a biotechnology company applying nanotechnology to biosensing. By leveraging their proprietary Plasmonic Chip, with technology licensed from the US Naval Research Laboratory, they allow scientists to see and measure, in real time, exactly how cells communicate by releasing and absorbing proteins in the “dark space” between them. It is not currently possible to image the release or absorption of these protein molecules in real-time in the extracellular space, limiting the exploration of cellular releases as potential therapeutic targets. Nanocrine’s patented technology resolves that limitation and, by allowing scientists to see how cells communicate, their technology will enable ground-breaking research in a number of critical use cases.

The applications of Nanocrine’s life sciences technology platform include:

• Cancer metastasis: the Plasmonic Chip can detect in real-time pre-metastatic niche signaling EVs (extracellular vesicles) and exosomes

• Cellular senescence: detection of senescence associated secretory phenotype (SASP) 

• Immune system health and responsiveness: detection of intercellular immunomodulatory signaling in real-time

• Neurodegenerative diseases: the Plasmonic Chip can detect circulating neurotoxic exosomes

The Plasmonic Chip can also be used to detect when a certain protein is being released by a cell, relative to other protein releases, and whether this changes in certain disease states. This new knowledge of cell protein releases in real-time will generate new discoveries to support both drug and diagnostic development. 

Nanocrine's commitment to enhancing experimental reproducibility and reducing preparation time is evident in their product design. All biochips come ready to use out of the packaging, which is a significant advantage in high-throughput research environments where time and consistency are critical. 

Please contact Mitchell Hauser for more information or to arrange a meeting with Patrick Calhoun, Nanocrine's CEO.

Biosensors, Plasmonic Assemblies, and Global Market Insights 

Biosensors are transforming healthcare and research for the better. They aid in detecting and monitoring diseases cost-effectively, enabling researchers and healthcare providers to address challenges such as food safety and human biology. They play a vital role in medical instruments, facilitating accurate identification of biomarkers and prompt treatment.

Global market insights

The biosensors market is growing rapidly, driven by increasing use in healthcare and other industries. Estimated to be worth USD 25.5 billion in 2021, it is projected to reach USD 36.7 billion by 2026, and USD 48.89 billion by 2030. The global biosensors market is highly competitive, and biosensors find applications in medical diagnosis, food safety, environmental monitoring, and biodefense.

Biosensing: A new era in research sciences and healthcare

Biosensors are analytical devices that turn biological responses into electrical signals. These devices are crucial for detecting and measuring substances in fields like healthcare and environmental monitoring. They are designed to be highly specific, targeting the desired substance in complex samples. They speed up experiments, like drug discovery, by providing real-time data and faster decision-making. In healthcare, biosensors are transforming patient monitoring and disease diagnosis, as in continuous glucose monitoring for diabetes. They're also crucial for quickly detecting infectious diseases like COVID-19, helping with early detection and disease control.

Plasmonic Assemblies for Real-Time Single-Molecule Biosensing

Plasmonic nanoparticles are incredibly useful in many applications. By arranging them in different configurations, we can make new materials with different optical properties, useful for biosensing and color printing.

In biosensing, these tiny particles can detect even the smallest amounts of biomarkers, like proteins or DNA, under a microscope. They're highly sensitive, able to detect changes caused by samples containing only one molecule of a given substance. This can help scientists understand chemical and biological functions and how they interact. Scientists are also using these nanoparticles to track how molecules move and change in real-time, shedding new light on how diseases start or how drugs work in the body. Nanocrine is deeply invested in applying nanotechnology to biosensing. Leveraging patented technology licensed from the US Naval Research Laboratory, Nanocrine's proprietary Plasmonic Imaging Chip (PIC) enables innovative cell phenotyping capabilities crucial for disease and infection analysis. Anticipated outcomes include advancements in therapeutic development, mitigating cancer metastasis, and reducing neurological decline in neurodegenerative conditions. Their endeavors hold promise for significant future achievements.

IUPAC. Compendium of Chemical Terminology - the Gold Book. Biosensor. 1997. Wang, J. Electrochemical biosensors: towards point-of-care cancer diagnostics

Biosens. Bioelectron., 21 (10) (2006), pp. 1887-1892

https://www.marketsandmarkets.com/Market-Reports/biosensors-market-798.html

https://onlinelibrary.wiley.com/doi/full/10.1002/smll.202003934

https://www.sciencedirect.com/science/article/pii/S2666351123000311#bib1

WAVE Drowning Prevention Systems continues to build momentum:

• WAVE added their second international sale, this time in Singapore, bringing the total systems sold to 103.

• WAVE'S award-winning drowning prevention technology was featured in the April issue of Athletic Business. To see the full article please click here.

  
  

Please contact Mitchell Hauser for more information or to arrange a meeting with Mark Caron, WAVE’s CEO.

The Company has made significant progress, most noticeably it has secured $1.7 million (USD) in bridge financing and is moving ahead to close on its next capital raise:

• AKOS has secured formal commitments to provide services for more than 120 wells in Canada

• AKOS has executed a 2-year joint-service delivery agreement with Trican Well Service to support work in the Canadian market

• AKOS will begin shipping equipment to Abu Dhabi in May 2024 ($24mm USD service agreement)

• AKOS has begun fabrication of all the equipment required in Saudi Arabia and plans to begin work in this region in Q3 2024 ($5mm service agreement)

  
  

Please contactMitchell Hauser for more information or to arrange a meeting with Kent Kalar, AKOS' CEO.

Jason Hanft, Defender's Founder and CEO, spoke at the Advanced Wound Care Summit USA in Boston on April 16th and 17th, 2024. 

Please contact Tony Coretto for more information or to arrange a meeting with Jason Hanft, Defender’s CEO.

We are happy to welcome Marjorie Ret to our team as an analyst for Strategic Ventures. She assists in doing research and client outreach. Before becoming a part of the SV team, Marj has years of experience in the sales department of the largest bank in the Philippines as an Account Representative handling loan accounts.